Zurcher Kantonalbank Zurich Cantonalbank Raises Position in Evolent Health, Inc. (NYSE:EVH)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,355 shares of the technology company’s stock after buying an additional 2,677 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Evolent Health were worth $771,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EVH. Gamco Investors INC. ET AL lifted its position in shares of Evolent Health by 0.5% during the third quarter. Gamco Investors INC. ET AL now owns 97,000 shares of the technology company’s stock worth $2,641,000 after purchasing an additional 500 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Evolent Health by 0.5% in the 3rd quarter. New York State Common Retirement Fund now owns 94,908 shares of the technology company’s stock worth $2,584,000 after buying an additional 506 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Evolent Health by 9.0% in the 3rd quarter. Teacher Retirement System of Texas now owns 8,293 shares of the technology company’s stock valued at $226,000 after buying an additional 685 shares during the last quarter. Genesee Capital Advisors LLC grew its stake in shares of Evolent Health by 2.2% during the fourth quarter. Genesee Capital Advisors LLC now owns 38,390 shares of the technology company’s stock valued at $1,268,000 after acquiring an additional 825 shares in the last quarter. Finally, Amalgamated Bank increased its position in shares of Evolent Health by 9.7% during the third quarter. Amalgamated Bank now owns 17,023 shares of the technology company’s stock worth $464,000 after acquiring an additional 1,500 shares during the last quarter.

Evolent Health Stock Up 0.6 %

NYSE:EVH opened at $27.82 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a 50 day moving average of $31.71 and a 200-day moving average of $30.29. The firm has a market capitalization of $3.21 billion, a PE ratio of -21.91 and a beta of 1.54. Evolent Health, Inc. has a 52 week low of $23.33 and a 52 week high of $36.70.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.13. The firm had revenue of $556.06 million during the quarter, compared to the consensus estimate of $541.87 million. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. Analysts predict that Evolent Health, Inc. will post 0.87 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Oppenheimer started coverage on Evolent Health in a research note on Friday, March 1st. They set an “outperform” rating and a $45.00 price objective for the company. Citigroup assumed coverage on shares of Evolent Health in a research report on Monday, April 22nd. They set a “buy” rating and a $40.00 price target for the company. JMP Securities upped their price target on shares of Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a report on Friday, February 23rd. JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. Finally, Canaccord Genuity Group cut their target price on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, March 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.70.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.